(Correcting the headline to clarify that Clinigen already had the products in its portfolio).
LONDON (Alliance News) - Clinigen Group PLC on Wednesday said it has agreed to retake the US commercial rights to oncology products Ethyol and Totect from Cumberland Pharmaceuticals Inc.
This agreement with Cumberland is the next step in Clinigen's Commercial Medicines strategy, the company explained. Following completion of the transition, expected in the fourth quarter of the year, Clinigen will have direct control of three oncology products currently available in the US.
Both Totect and Ethyol have been part of Clinigen's portfolio for several years, with the US sales managed by Cumberland on the company's behalf.
Clinigen will begin to recognise the total benefit of in-market product sales in the first full-year post transition of commercial rights, being its year ending June 2021, with a limited financial impact in financial 2020.
